The positive impact of NPM1 and IDH2R172 and negative impact of TP53 has previously been reported but not uniformly so by all previous studies on elderly AML patients9–12, possibly due to diversity in patient populations, sensitivity of mutational screening and differences in patient numbers. Here, TP53 is linked to acute myeloid leukemia.